Evofem Biosciences to Participate in Stifel 2021 Virtual Healthcare Conference

SAN DIEGO, Nov. 4, 2021 / PRNewswire -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier will participate in the Stifel 2021 Virtual Healthcare Conference as follows:

| Date | Tuesday, November 16, 2021 |
|---------------------------|---|
| Time | 1:20 p.m. ET |
| Format | Fireside Chat |
| Room | Track 2 |
| Webcast (live and replay) | https://wsw.com/webcast/stifel58/evfm/2096280 |

The webcast will be archived in the Events and Presentations section of the Company's website at https://evofem.investorroom.com/Stifel2021.

Additionally, Evofem Biosciences will host one-on-one meetings on Tuesday, November 16, 2021. Meetings can be requested exclusively via Stifel.

About Evofem Biosciences

Evofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (chlamydia and gonorrhea). The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com and evofem.com.

Phexxi[®] is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact

Amy Raskopf Evofem Biosciences, Inc. araskopf@evofem.com Mobile: (917) 673-5775

SOURCE Evofem Biosciences, Inc.